Capsugel Launches New Oral Formulation Business Unit

By Dan Stanton

- Last updated on GMT

Related tags Pharmacology

Capsugel announce new dosage form business unit
Capsugel announce new dosage form business unit
Capsugel says it will focus on lipid-based formulations as it launches a new Dosage Form Solutions Business Unit.

The new unit, based at the company’s headquarters in Morristown, New Jersey, will integrate formulation R&D with proprietary technology and commercial manufacturing as Capsugel aims to develop innovative products to address customer demand.

Amit Patel, who will serve as President of the Unit, said in a press release that “continuing to innovate and develop cutting-edge healthcare products is essential to maximizing the potential of the industry.”

Lipid-based Formulations

Patel also said that the new unit would focus on improvements in solid oral dosage products, including bioavailability enhancement and optimal dosing for potent APIs, and especially lipid-based formulations.

Lipid-based drug delivery systems (LBDDs) are an increasingly more important drug delivery technique as drugs become more complex and less soluble in water. LBDDs are a versatile way of enabling a higher dose to be encapsulated and more API to be absorbed.

Last June, Capsugel entered into a partnership with Quotient​ in order to boost its LBDDs know-how and two months later launched a non-profit consortium in order to establish a lipid formulation classification system.

Oral Formulation Driven by Bioavailability

Recently there has been a flow of collaborations and investments in the oral dose formulation sector as companies vie to lead the way in bioavailability.

This week in-Pharmatechnologist.com reported that Dow, Cambrex and Bend Research​ have formed a trifecta to tackle the issue, and Hovione and Solvias​ also teamed up late last year. Patheon, Catalent​ and Polypid​ have also heavily invested in oral dose formulation platforms. 

On the 20th​ March the Bioavailability Challenge will be addressed in a special online event, organized by in-Pharmatechnologist.com. For more information on speakers and how to gain access to the event, please click here​.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us

Products

View more

Webinars